Molecule News and Research

RSS

International researchers solve three-dimensional structure of respiratory syncytial virus

Young children and the elderly are especially susceptible to respiratory syncytial virus. The three-dimensional structure of respiratory syncytial virus has been solved by an international team from Finland and Switzerland.

18 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

Researchers produce first genome-wide investigation of cap-independent translation

Because of their central importance to biology, proteins have been the focus of intense research, particularly the manner in which they are produced from genetically coded templates-a process commonly known as translation. While the general mechanism of translation has been understood for some time, protein synthesis can initiate by more than one mechanism. One of the least well understood mechanisms is known as cap-independent translation.

17 Jun 2013

Scientists find that psychiatric disorders may be linked to protein involved in memory formation

Researchers have discovered a pathway by which the brain controls a molecule critical to forming long-term memories and connected with bipolar disorder and schizophrenia.

17 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

New research reports that UnaG protein could lead to new liver test

Many scientists dream of making a single discovery that provides fundamental insight into nature, may be used to help save human lives, and can assist in the preservation of an endangered species. In new research reported in the journal Cell, a Japanese team is on the verge of accomplishing this nearly impossible feat.

17 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Penn researchers develop variant of mu opioid painkiller receptor to overcome side effects

Opioids, such as morphine, are still the most effective class of painkillers, but they come with unwanted side effects and can also be addictive and deadly at high doses. Designing new pain-killing drugs of this type involves testing them on their corresponding receptors, but access to meaningful quantities of these receptors that can work in experimental conditions has always been a limiting factor.

15 Jun 2013

Too much sugar can lead to heart failure, shows study

Too much sugar can set people down a pathway to heart failure, according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).

15 Jun 2013

UCSF researchers discover memory-boosting molecule in mice

Memory improved in mice injected with a small, drug-like molecule discovered by UCSF San Francisco researchers studying how cells respond to biological stress.

15 Jun 2013

Acrolein offers potential tool to reduce symptoms of spinal cord injuries and multiple sclerosis

A medical test previously developed to measure a toxin found in tobacco smokers has been adapted to measure the same toxin in people suffering from spinal cord injuries and multiple sclerosis, offering a potential tool to reduce symptoms.

14 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Penn Medicine researchers identify key molecular player in recurrent breast cancer

According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence - the reappearance of the disease following treatment.

14 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Chemotherapy devices: an interview with Damien Salauze, head of Curie-Cancer

Although several chemotherapy treatments are now administered by the oral route (targeted chemotherapy), most chemotherapy treatments (cytotoxics) are administered by the intravenous route.

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

12 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Molecule News and Research

International researchers solve three-dimensional structure of respiratory syncytial virus

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

Researchers produce first genome-wide investigation of cap-independent translation

Scientists find that psychiatric disorders may be linked to protein involved in memory formation

Mount Sinai researchers present several new studies at ENDO 2013

New research reports that UnaG protein could lead to new liver test

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Penn researchers develop variant of mu opioid painkiller receptor to overcome side effects

Too much sugar can lead to heart failure, shows study

UCSF researchers discover memory-boosting molecule in mice

Acrolein offers potential tool to reduce symptoms of spinal cord injuries and multiple sclerosis

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Penn Medicine researchers identify key molecular player in recurrent breast cancer

PRISM Pharma announces closing of $15 million Series C financing

Chemotherapy devices: an interview with Damien Salauze, head of Curie-Cancer

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News